Radiopharm and TerraPower sign Actinium 225 agreement
Filed with ASX · · 2 pages · English
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- RAD acquires IP Ownership of Radiopharmaceutical Nanobodies
- RAD Integrins technology featured in Cancers journal
Later from Radiopharm Theranostics
- LOI with GenesisCare to start first trial in Australia
- RAD Licenses UCLA Dual Action Antibody
- FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
- FDA grants rare pediatric disease designation for DUNP19
- Suspension from Official Quotation
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics